QQQ   313.77 (+0.30%)
AAPL   122.00 (+0.83%)
MSFT   231.24 (+0.98%)
FB   258.21 (+1.38%)
GOOGL   2,019.56 (+0.18%)
AMZN   3,067.18 (+0.33%)
TSLA   673.26 (-1.31%)
NVDA   544.14 (+2.22%)
BABA   239.19 (-0.41%)
CGC   32.88 (-0.99%)
GE   12.50 (-2.04%)
MU   89.56 (+1.63%)
NIO   45.13 (-3.59%)
AMD   83.64 (+1.48%)
T   28.43 (-0.70%)
F   11.65 (-0.94%)
ACB   10.80 (-0.18%)
DIS   187.28 (-1.94%)
BA   215.23 (-0.56%)
NFLX   541.67 (-0.92%)
BAC   35.17 (-2.12%)
QQQ   313.77 (+0.30%)
AAPL   122.00 (+0.83%)
MSFT   231.24 (+0.98%)
FB   258.21 (+1.38%)
GOOGL   2,019.56 (+0.18%)
AMZN   3,067.18 (+0.33%)
TSLA   673.26 (-1.31%)
NVDA   544.14 (+2.22%)
BABA   239.19 (-0.41%)
CGC   32.88 (-0.99%)
GE   12.50 (-2.04%)
MU   89.56 (+1.63%)
NIO   45.13 (-3.59%)
AMD   83.64 (+1.48%)
T   28.43 (-0.70%)
F   11.65 (-0.94%)
ACB   10.80 (-0.18%)
DIS   187.28 (-1.94%)
BA   215.23 (-0.56%)
NFLX   541.67 (-0.92%)
BAC   35.17 (-2.12%)
QQQ   313.77 (+0.30%)
AAPL   122.00 (+0.83%)
MSFT   231.24 (+0.98%)
FB   258.21 (+1.38%)
GOOGL   2,019.56 (+0.18%)
AMZN   3,067.18 (+0.33%)
TSLA   673.26 (-1.31%)
NVDA   544.14 (+2.22%)
BABA   239.19 (-0.41%)
CGC   32.88 (-0.99%)
GE   12.50 (-2.04%)
MU   89.56 (+1.63%)
NIO   45.13 (-3.59%)
AMD   83.64 (+1.48%)
T   28.43 (-0.70%)
F   11.65 (-0.94%)
ACB   10.80 (-0.18%)
DIS   187.28 (-1.94%)
BA   215.23 (-0.56%)
NFLX   541.67 (-0.92%)
BAC   35.17 (-2.12%)
QQQ   313.77 (+0.30%)
AAPL   122.00 (+0.83%)
MSFT   231.24 (+0.98%)
FB   258.21 (+1.38%)
GOOGL   2,019.56 (+0.18%)
AMZN   3,067.18 (+0.33%)
TSLA   673.26 (-1.31%)
NVDA   544.14 (+2.22%)
BABA   239.19 (-0.41%)
CGC   32.88 (-0.99%)
GE   12.50 (-2.04%)
MU   89.56 (+1.63%)
NIO   45.13 (-3.59%)
AMD   83.64 (+1.48%)
T   28.43 (-0.70%)
F   11.65 (-0.94%)
ACB   10.80 (-0.18%)
DIS   187.28 (-1.94%)
BA   215.23 (-0.56%)
NFLX   541.67 (-0.92%)
BAC   35.17 (-2.12%)
Log in
NASDAQ:FATE

Fate Therapeutics Stock Forecast, Price & News

$88.40
+2.13 (+2.47 %)
(As of 02/26/2021 10:04 AM ET)
Add
Compare
Today's Range
$86.51
Now: $88.40
$93.28
50-Day Range
$87.52
MA: $104.06
$117.40
52-Week Range
$16.75
Now: $88.40
$121.16
Volume12,210 shs
Average Volume1.08 million shs
Market Capitalization$7.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Fate Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800
Employees178
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.68 million
Book Value$3.24 per share

Profitability

Net Income$-98,150,000.00
Net Margins-810.13%

Miscellaneous

Market Cap$7.71 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

331st out of 1,957 stocks

Biological Products, Except Diagnostic Industry

44th out of 177 stocks

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
$88.40
+2.13 (+2.47 %)
(As of 02/26/2021 10:04 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

Is Fate Therapeutics a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fate Therapeutics stock.
View analyst ratings for Fate Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Fate Therapeutics?

Wall Street analysts have given Fate Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fate Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Fate Therapeutics
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its earnings results on Wednesday, February, 24th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.23. Fate Therapeutics had a negative trailing twelve-month return on equity of 35.51% and a negative net margin of 810.13%.
View Fate Therapeutics' earnings history
.

How has Fate Therapeutics' stock price been impacted by COVID-19?

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FATE stock has increased by 273.0% and is now trading at $88.73.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for FATE?

15 brokerages have issued twelve-month price targets for Fate Therapeutics' shares. Their forecasts range from $41.00 to $135.00. On average, they anticipate Fate Therapeutics' share price to reach $88.32 in the next twelve months. This suggests that the stock has a possible downside of 0.5%.
View analysts' price targets for Fate Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the following people:
  • Mr. J. Scott Wolchko, Founder, CEO, Pres & Director (Age 51, Pay $850.5k)
  • Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 53, Pay $525.94k)
  • Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 48, Pay $525.94k)
  • Dr. Bahram Valamehr Ph.D., Chief Devel. Officer (Age 44, Pay $525.94k)
  • Mr. Edward J. Dulac III, CFO & Principal Accounting Officer (Age 46)
  • Dr. Wen Bo Wang, Sr. VP of Technical Operations
  • Mr. Jim Beitel M.B.A., Sr. VP of Corp. Devel.
  • Dr. Sarah Cooley, Sr. VP of Clinical Translation
  • Dr. Yu-Waye Chu M.D., Sr. VP of Clinical Devel.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics CEO Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among Fate Therapeutics' employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Fate Therapeutics' key competitors?

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), 1877 (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.65%), Price T Rowe Associates Inc. MD (4.02%), Janus Henderson Group PLC (2.92%), Victory Capital Management Inc. (2.01%), Artal Group S.A. (1.60%) and Morgan Stanley (1.11%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc.
View institutional ownership trends for Fate Therapeutics
.

Which major investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Janus Henderson Group PLC, Polaris Venture Management Co. V L.L.C., Artal Group S.A., SG Americas Securities LLC, Asymmetry Capital Management L.P., Nuveen Asset Management LLC, and Assenagon Asset Management S.A.. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, and J Scott Wolchko.
View insider buying and selling activity for Fate Therapeutics
or view top insider-selling stocks.

Which major investors are buying Fate Therapeutics stock?

FATE stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Darwin Global Management Ltd., Lone Pine Capital LLC, Morgan Stanley, Amundi Pioneer Asset Management Inc., Candriam Luxembourg S.C.A., BlackRock Inc., and Rice Hall James & Associates LLC.
View insider buying and selling activity for Fate Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $88.73.

How much money does Fate Therapeutics make?

Fate Therapeutics has a market capitalization of $7.74 billion and generates $10.68 million in revenue each year. The biopharmaceutical company earns $-98,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

How many employees does Fate Therapeutics have?

Fate Therapeutics employs 178 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Where are Fate Therapeutics' headquarters?

Fate Therapeutics is headquartered at 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.